Compare TG Therapeutics Inc (TGTX) vs VNET Group Inc (VNET) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs VNET Group Inc — how do they compare? TG Therapeutics Inc trades at $54.77 (market cap $8.36B), while VNET Group Inc trades at $6.5 (market cap $1.86B). The key difference: TG Therapeutics Inc is far larger — about 4.5× VNET Group Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, VNET Group Inc nearer its low. Which is the better fit depends on your goals.
| TGTX | VNET | |
|---|---|---|
Market Cap | $8.36B | $1.86B |
Sector | Health | Technology |
52-Week High | $59.06 | $14.03 |
52-Week Low | $26.94 | $6.06 |
Enterprise Value | $8.57B | $5.42B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The stock shows strong profitability with a net income margin of 55.22% and ROE of 100.28%, though recent quarters have seen earnings misses. Revenue growth is robust, with 2026 guidance raised to $950 million for BRIUMVI, and buyout rumors have fueled positive sentiment.
The outlook for TGTX is positive driven by BRIUMVI's commercial success and pipeline catalysts, but risks include earnings volatility, high valuation multiples, and competitive pressures. Institutional accumulation supports upside, yet investors should weigh execution risks against growth potential.
VNET trades at $6.75, up 5.97% today, amid a bearish technical signal. The company reported Q2 2026 revenue growth driven by wholesale data center demand but missed EPS estimates, with a net loss of $256.77 million in 2025. Analyst consensus is 62.5% buy, though a class action settlement and rising leverage pose risks.
Outlook is mixed: strategic cooperation with CATL and secured capacity support growth, but negative margins, high debt, and cash flow concerns challenge profitability. Investors face upside from AI infrastructure demand against balance sheet and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About VNET Group Inc
VNET Group, formerly 21Vianet, is a leading carrier-neutral data center services provider in China. It operates a dual-core strategy: a large-scale retail business serving over 7,000 enterprise customers and an aggressive wholesale segment (Hyperscale 2.0) designed to meet the high-density power and cooling demands of large-scale AI and cloud platforms.
Read more on VNET →
